Edwards Lifesciences Corporation $EW Shares Sold by AE Wealth Management LLC

AE Wealth Management LLC lowered its stake in Edwards Lifesciences Corporation (NYSE:EW) by 94.5% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 5,024 shares of the medical research company’s stock after selling 86,731 shares during the quarter. AE Wealth Management LLC’s holdings in Edwards Lifesciences were worth $391,000 as of its most recent filing with the SEC.

Other hedge funds also recently bought and sold shares of the company. Econ Financial Services Corp purchased a new stake in Edwards Lifesciences during the second quarter worth approximately $889,000. Fjarde AP Fonden Fourth Swedish National Pension Fund lifted its holdings in shares of Edwards Lifesciences by 7.0% during the 3rd quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 137,835 shares of the medical research company’s stock valued at $10,719,000 after acquiring an additional 9,069 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in Edwards Lifesciences by 13.2% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 86,235 shares of the medical research company’s stock worth $6,706,000 after purchasing an additional 10,078 shares during the period. OMERS ADMINISTRATION Corp increased its holdings in Edwards Lifesciences by 97.3% in the 2nd quarter. OMERS ADMINISTRATION Corp now owns 44,504 shares of the medical research company’s stock valued at $3,481,000 after purchasing an additional 21,950 shares in the last quarter. Finally, Arkadios Wealth Advisors purchased a new position in Edwards Lifesciences in the second quarter valued at about $300,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Stock Down 2.1%

Shares of Edwards Lifesciences stock opened at $78.06 on Friday. The company has a quick ratio of 3.29, a current ratio of 4.00 and a debt-to-equity ratio of 0.06. The business has a 50-day moving average price of $84.31 and a 200 day moving average price of $81.08. Edwards Lifesciences Corporation has a fifty-two week low of $65.94 and a fifty-two week high of $87.89. The firm has a market cap of $45.30 billion, a P/E ratio of 33.65, a P/E/G ratio of 3.07 and a beta of 0.94.

Analysts Set New Price Targets

Several brokerages recently commented on EW. Robert W. Baird set a $90.00 target price on Edwards Lifesciences in a report on Monday, January 12th. National Bankshares set a $92.00 price objective on shares of Edwards Lifesciences in a research note on Friday, October 31st. Mizuho upped their target price on shares of Edwards Lifesciences from $90.00 to $100.00 and gave the company an “outperform” rating in a research note on Friday, October 31st. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Edwards Lifesciences in a report on Wednesday, January 21st. Finally, Truist Financial set a $92.00 price objective on shares of Edwards Lifesciences and gave the stock a “hold” rating in a report on Friday, December 5th. Three research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Edwards Lifesciences presently has an average rating of “Moderate Buy” and an average target price of $96.77.

Insiders Place Their Bets

In other news, VP Donald E. Bobo, Jr. sold 11,386 shares of Edwards Lifesciences stock in a transaction dated Friday, December 12th. The shares were sold at an average price of $83.76, for a total value of $953,691.36. Following the completion of the transaction, the vice president directly owned 38,970 shares of the company’s stock, valued at approximately $3,264,127.20. The trade was a 22.61% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, VP Daniel J. Lippis sold 1,020 shares of the business’s stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $82.55, for a total transaction of $84,201.00. Following the sale, the vice president directly owned 22,002 shares of the company’s stock, valued at approximately $1,816,265.10. This represents a 4.43% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 57,824 shares of company stock valued at $4,863,323 over the last 90 days. 1.29% of the stock is owned by company insiders.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.